Talking about sex: erectile dysfunction in the oncology patient.

IF 4.1 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM Endocrine-related cancer Pub Date : 2023-06-01 DOI:10.1530/ERC-22-0401
Marilina Romeo, Giorgia Spaggiari, Chiara Furini, Antonio R M Granata, Angela Toss, Manuela Simoni, Daniele Santi
{"title":"Talking about sex: erectile dysfunction in the oncology patient.","authors":"Marilina Romeo,&nbsp;Giorgia Spaggiari,&nbsp;Chiara Furini,&nbsp;Antonio R M Granata,&nbsp;Angela Toss,&nbsp;Manuela Simoni,&nbsp;Daniele Santi","doi":"10.1530/ERC-22-0401","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer-related diagnosis and treatments can profoundly affect every aspect of an individual's life. The negative impact on the sexual sphere can manifest with onset or worsening of the most frequent male form of sexual dysfunction, that is the erectile dysfunction (ED), with an estimated incidence ranging from 40 to 100% in patients living with cancer. Cancer and ED are strictly related for many reasons. First, the psychological distress, the so-called 'Damocles syndrome', afflicting cancer patients contributes to ED onset. Second, all cancer therapies can variably lead to sexual dysfunction, even more than the disease itself, having both direct or indirect effects on sexual life. Indeed, alongside pelvic surgery and treatments directly impairing the hypothalamus-pituitary-gonadal axis, the altered personal-body-image frequently experienced by people living with cancer may represent a source of distress contributing to sexual dysfunction. It is undeniable that sexual issues are currently neglected or at least under-considered in the oncological setting, mainly due to the subjective lack of preparation experienced by healthcare professionals and to scant information provided to oncological patients on this topic. To overcome these management problems, a new multidisciplinary medical branch called 'oncosexology' was set up. The aim of this review is to comprehensively evaluate ED as an oncology-related morbidity, giving new light to sexual dysfunction management in the oncological setting.</p>","PeriodicalId":11654,"journal":{"name":"Endocrine-related cancer","volume":"30 6","pages":""},"PeriodicalIF":4.1000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine-related cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1530/ERC-22-0401","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Cancer-related diagnosis and treatments can profoundly affect every aspect of an individual's life. The negative impact on the sexual sphere can manifest with onset or worsening of the most frequent male form of sexual dysfunction, that is the erectile dysfunction (ED), with an estimated incidence ranging from 40 to 100% in patients living with cancer. Cancer and ED are strictly related for many reasons. First, the psychological distress, the so-called 'Damocles syndrome', afflicting cancer patients contributes to ED onset. Second, all cancer therapies can variably lead to sexual dysfunction, even more than the disease itself, having both direct or indirect effects on sexual life. Indeed, alongside pelvic surgery and treatments directly impairing the hypothalamus-pituitary-gonadal axis, the altered personal-body-image frequently experienced by people living with cancer may represent a source of distress contributing to sexual dysfunction. It is undeniable that sexual issues are currently neglected or at least under-considered in the oncological setting, mainly due to the subjective lack of preparation experienced by healthcare professionals and to scant information provided to oncological patients on this topic. To overcome these management problems, a new multidisciplinary medical branch called 'oncosexology' was set up. The aim of this review is to comprehensively evaluate ED as an oncology-related morbidity, giving new light to sexual dysfunction management in the oncological setting.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
谈论性:肿瘤患者的勃起功能障碍。
癌症相关的诊断和治疗可以深刻地影响个人生活的方方面面。对性领域的负面影响可以表现为最常见的男性性功能障碍的发作或恶化,即勃起功能障碍(ED),据估计,癌症患者的发病率从40%到100%不等。由于许多原因,癌症和ED密切相关。首先,折磨癌症患者的心理困扰,即所谓的“达摩克利斯综合症”,是ED发病的原因之一。其次,所有的癌症治疗都可能导致性功能障碍,甚至比疾病本身更严重,对性生活有直接或间接的影响。事实上,除了骨盆手术和直接损害下丘脑-垂体-性腺轴的治疗外,癌症患者经常经历的个人身体形象的改变可能是导致性功能障碍的痛苦来源。不可否认的是,性问题目前在肿瘤环境中被忽视或至少没有得到充分的考虑,主要是由于卫生保健专业人员主观缺乏准备,以及向肿瘤患者提供的关于这一主题的信息不足。为了克服这些管理问题,建立了一个新的多学科医学分支,称为“肿瘤学”。本文综述的目的是全面评价ED作为一种肿瘤学相关疾病,为肿瘤学环境中的性功能障碍管理提供新的视角。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Endocrine-related cancer
Endocrine-related cancer 医学-内分泌学与代谢
CiteScore
7.80
自引率
2.60%
发文量
138
审稿时长
6-12 weeks
期刊介绍: Endocrine-Related Cancer is an official flagship journal of the Society for Endocrinology and is endorsed by the European Society of Endocrinology, the United Kingdom and Ireland Neuroendocrine Society, and the Japanese Hormones and Cancer Society. Endocrine-Related Cancer provides a unique international forum for the publication of high quality original articles describing novel, cutting edge basic laboratory, translational and clinical investigations of human health and disease focusing on endocrine neoplasias and hormone-dependent cancers; and for the publication of authoritative review articles in these topics. Endocrine neoplasias include adrenal cortex, breast, multiple endocrine neoplasia, neuroendocrine tumours, ovary, prostate, paraganglioma, parathyroid, pheochromocytoma pituitary, testes, thyroid and hormone-dependent cancers. Neoplasias affecting metabolism and energy production such as bladder, bone, kidney, lung, and head and neck, are also considered.
期刊最新文献
Cushing syndrome from an ACTH-producing pheochromocytoma or paraganglioma: structured review of 94 cases GPNMB promotes tumor growth and is a biomarker for lymphangioleiomyomatosis Neuropilin-2 and soluble neuropilin-2 in neuroendocrine neoplasms Importance of 3β-hydroxysteroid dehydrogenases and their clinical use in prostate cancer Genetic disorders and insulinoma/glucagonoma
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1